Cannonau Corp. (CNNC) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
P/E 0.00 means the share price is 0.00 times one year of earnings per share. Beta 1.52: the stock has moved about 52% more than the S&P 500.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 16, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerCannonau Corp. (CNNC) trades at $0.0001. Cannonau Corp. focuses on developing cannabidiol-based products. The company, formerly Pacific Blue Energy Corp., changed its name in August 2019 and is based in Skaneateles, New York. Sector: Healthcare.
Price as of · Last analyzed: Mar 16, 2026Analyst Coverage for CNNC: CNNC does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
Cannonau Corp. (CNNC) Healthcare & Pipeline Overview
Cannonau Corp., a small-cap company in the specialty and generic drug manufacturing sector, focuses on developing cannabidiol-based products. Formerly Pacific Blue Energy Corp., the company operates from Skaneateles, New York, and faces competition in the rapidly evolving CBD market.
What Is the Investment Thesis for CNNC?
Cannonau Corp. presents a speculative investment opportunity within the high-growth CBD market. The company's small size and limited operating history introduce significant risks. Key value drivers include successful product development and market penetration within the competitive CBD landscape. The company's ability to secure funding and navigate regulatory hurdles will be critical for long-term viability. With a market capitalization of $0.00B and a P/E ratio of 0.00, traditional valuation metrics offer limited insight. The company's beta of 1.52 indicates higher volatility compared to the broader market. Investors should carefully consider the risks associated with investing in a small, OTC-listed company in a rapidly evolving industry.
Based on FMP financials and quantitative analysis
CNNC Key Highlights
Cannonau Corp. focuses on the development of cannabidiol (CBD) based products, tapping into the growing market for alternative health solutions.
- The company was formerly known as Pacific Blue Energy Corp., indicating a strategic shift in business focus towards the healthcare sector in August 2019.
- Cannonau Corp. is based in Skaneateles, New York, operating with a small team of 4 employees.
- The company's market capitalization is $0.00B, reflecting its early stage and potential for growth or risk.
- Cannonau Corp. trades on the OTC market, which typically involves higher risk and lower liquidity compared to major exchanges.
Who Are CNNC's Competitors?
CNNC is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| TAK Takeda Pharmaceutical Company Limited | $17.86 | 0.00% | $56.8B | — |
| TEVA Teva Pharmaceutical Industries Limited | $39.53 | +0.56% | $46.0B | — |
| HLN Haleon plc | $8.80 | +0.92% | $38.8B | — |
| ZTS Zoetis Inc. | $69.69 | +0.85% | $29.2B | — |
| VTRS Viatris Inc. | $17.60 | +0.80% | $20.5B | — |
| ELAN Elanco Animal Health Incorporated | $22.14 | +1.70% | $11.1B | — |
| RDY Dr. Reddy's Laboratories Limited | $12.25 | 0.00% | $10.2B | — |
| LNTH Lantheus Holdings, Inc. | $99.96 | +0.31% | $6.51B | — |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are CNNC's Key Strengths?
Focus on the growing CBD market.
- Potential for innovative product development.
- Strategic shift towards healthcare applications.
- Small size allows for agility and adaptability.
What Are CNNC's Weaknesses?
Limited financial resources.
- Small team and limited operational capacity.
- Lack of established brand recognition.
- Dependence on a single product category (CBD).
What Are the Key Risks for CNNC?
Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Intense competition from larger companies in the CBD market.
- Evolving regulatory landscape could restrict the sale or marketing of CBD products.
- Negative publicity or safety concerns related to CBD could damage consumer confidence.
- Fluctuations in the price of CBD raw materials could impact profitability.
- Limited financial resources may hinder Cannonau Corp.'s ability to compete effectively.
What Are CNNC's Competitive Advantages?
- Proprietary CBD formulations (if any).
- Brand recognition and customer loyalty (if established).
- Strategic partnerships with distributors or retailers.
- Intellectual property protection through patents (if any).
What Does CNNC Do?
Cannonau Corp., established in 2007 and formerly known as Pacific Blue Energy Corp., transitioned its focus to the development of cannabidiol (CBD) based products in August 2019. Headquartered in Skaneateles, New York, the company operates within the specialty and generic drug manufacturing industry, specifically targeting the burgeoning CBD market. Cannonau Corp. aims to capitalize on the increasing consumer interest in CBD for various health and wellness applications. As a relatively small player with only 4 employees, Cannonau Corp. faces the challenge of competing with larger, more established companies in the pharmaceutical and wellness sectors. The company's success hinges on its ability to innovate, develop effective CBD products, and establish a strong market presence in a competitive landscape. The company's evolution from Pacific Blue Energy Corp. signals a strategic shift towards the healthcare sector, specifically focusing on the potential of cannabidiol-based therapies and products.
What Products and Services Does CNNC Offer?
- Develop cannabidiol (CBD) based products.
- Focus on the healthcare sector with CBD applications.
- Operate as a specialty and generic drug manufacturer.
- Engage in research and development for new CBD formulations.
- Market and distribute CBD products to consumers.
- Explore potential therapeutic applications of CBD.
How Does CNNC Make Money?
- Develop and formulate CBD-based products.
- Market and sell these products directly to consumers or through retail channels.
- Generate revenue through product sales.
- Potentially license or partner for distribution and manufacturing.
What Industry Does CNNC Operate In?
Cannonau Corp. operates in the Drug Manufacturers - Specialty & Generic industry, specifically targeting the cannabidiol (CBD) market. This market has experienced rapid growth in recent years, driven by increasing consumer awareness of CBD's potential health benefits. However, the industry is also characterized by intense competition and evolving regulatory landscapes. Companies like ACUR, AZFL, CBDX, FIORF, and FLHLF also compete in this space. Cannonau Corp.'s success depends on its ability to differentiate its products and navigate the complex regulatory environment.
Who Are CNNC's Key Customers?
- Individuals seeking alternative health and wellness solutions.
- Consumers interested in the potential therapeutic benefits of CBD.
- Retailers and distributors of health and wellness products.
- Potential partnerships with healthcare providers.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Company Profile
Cannonau Corp. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Skaneateles, US. The company is led by CEO Markwin Maring. CNNC has traded publicly since 2010.
Key Financial Metrics
CNNC trades at a trailing price-to-earnings ratio of 0.00, below the Healthcare sector average of ~21.10x. Its free cash flow yield is -0.2%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.03 means current liabilities exceed short-term assets, a liquidity point worth watching.
Financial Health
Cannonau Corp.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
CNNC Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
CNNC Latest News
No recent news available for CNNC.
CNNC Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for CNNC.
Price Targets
Wall Street price target analysis for CNNC.
CNNC MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for CNNC; grades run from A+ (80-100) to F (below 30).
Leadership: Markwin Maring
CEO
Markwin Maring serves as the CEO of Cannonau Corp., leading a small team of 4 employees. As the CEO, he is responsible for the overall strategic direction and operational management of the company, guiding its focus on developing cannabidiol-based products. His leadership is crucial for navigating the competitive CBD market and achieving the company's growth objectives.
Track Record: Due to limited information, Markwin Maring's specific achievements, strategic decisions, and company milestones under his leadership at Cannonau Corp. are currently unknown. Evaluating his track record requires further data on the company's performance and strategic initiatives since he assumed the role of CEO.
CNNC OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Cannonau Corp. may not meet the minimum financial standards or disclosure requirements for higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial reporting and may not be subject to the same regulatory oversight as companies listed on major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier carries significant risks due to the lack of transparency and potential for fraud or manipulation. Investors should exercise extreme caution and conduct thorough due diligence before investing in these companies.
- OTC Tier: OTC Other
- Limited financial disclosure and transparency.
- Low trading volume and liquidity.
- Potential for price manipulation.
- Higher risk of fraud or mismanagement.
- Limited regulatory oversight.
- Verify the company's registration and legal status.
- Obtain and review any available financial statements.
- Assess the company's management team and their experience.
- Research the company's business model and competitive landscape.
- Evaluate the company's regulatory compliance.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before investing.
- Company has been in operation since 2007.
- Company has a website and contact information.
- Company has a stated business focus (CBD products).
- Company has a CEO and a small team of employees.
- Company has undergone a name change to reflect its current focus.
CNNC Healthcare Stock FAQ
What do analysts say about CNNC stock?
There is currently no available analyst coverage for Cannonau Corp. (CNNC). As a small, OTC-listed company with a limited operating history, CNNC does not attract coverage from major financial analysts. Investors should rely on their own independent research and due diligence to assess the company's potential and risks.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Limited information available on Cannonau Corp. due to its OTC listing and small size.
- Financial data is limited, making it difficult to assess the company's true value and potential.